

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for July 2023

## Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sivem Pharmaceuticals	Olanzapine	Zyprexa	OLANZAPINE	20 mg	tablet	02385910
Jamp Pharma Corporation	Jamp Pomalidomide	Pomalyst	POMALIDOMIDE	1 mg	capsule	02538059
Jamp Pharma Corporation	Jamp Pomalidomide	Pomalyst	POMALIDOMIDE	2 mg	capsule	02538075
Jamp Pharma Corporation	Jamp Pomalidomide	Pomalyst	POMALIDOMIDE	3 mg	capsule	02538083
Jamp Pharma Corporation	Jamp Pomalidomide	Pomalyst	POMALIDOMIDE	4 mg	capsule	02538091
Mint Pharmaceuticals Inc.	Mint-Tadalafil	Cialis	TADALAFIL	10 mg	tablet	02451689

Auro Pharma Inc.	Auro-Sunitinib	Sutent	SUNITINIB MALATE	12.5 mg	capsule	02532190
Auro Pharma Inc.	Auro-Sunitinib	Sutent	SUNITINIB MALATE	25 mg	capsule	02532204
Auro Pharma Inc.	Auro-Sunitinib	Sutent	SUNITINIB MALATE	50 mg	capsule	02532220
Viartis Canada	Mylan-Azelastine/ Fluticasone	Dymista	AZELASTINE HCl/FLUTICASONE PROPIONATE	137 mcg/ACT/ 50 mcg/ACT	spray, metered dose	02530341
Sanis Health Inc.	Frovatriptan	Frova	FROVATRIPTAN SUCCINATE	2.5 mg	tablet	02535475
Marcan Pharmaceuticals Inc.	Mar-Metformin	Glucophage	METFORMIN HCl	850 mg	tablet	02378639